MEDOVEX CORP. (NASDAQ:MDVX) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure
On November 16, 2017, MedoveX Corporation (the “Company”) issued a press release containing an open letter to the Company’s shareholders from the Company’s Chief Executive Officer, Jarrett Gorlin. A copy of the press release is attached to this Current Report as Exhibit 99.1 and shall not be deemed incorporated by reference into any of the Company’s registration statements or other filings with the Securities & Exchange Commission, except as shall be expressly set forth by specific reference in such filing.
The information in this Item 7.01 disclosure, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. In addition, the information in this Item 7.01 disclosure, including Exhibits 99.1 and 99.2, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| Exhibit Number | Description |
| 99.1 | Press Release dated November 16, 2017 |
Medovex Corp. ExhibitEX-99.1 2 ex99-1.htm EXHIBIT 99.1 Medovex Corporation Releases Letter to Shareholders ATLANTA,…To view the full exhibit click here
